EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor

Georges Gebrael iD, Yeonjung Jo, Vinay Mathew Thomas, Haoran Li, Nicolas Sayegh, Nishita Tripathi iD, Ayana Srivastava, Blake Nordblad iD, Emre Dal, Arshit Narang, James Brundage, Patrick Campbell und 5 weitere

Cancer · 2024

DOI: 10.1002/cncr.35302 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer, 2024. Verfasst von Georges Gebrael und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Pyridines, Anilides, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Rechallenge with antibodies targeting programmed cell death protein‐1 or its ligand (PD‐1/L1) after discontinuation or disease progression in solid tumors following a prior PD‐1/L1 treatment is often practiced in clinic. This study aimed to investigate if adding PD‐1/L1 inhibitors to cabozantinib, the most used second‐line treatment in real‐world patients with metastatic clear cell renal cell carcinoma (mccRCC), offers additional benefits.

Methods

Using de‐identified patient‐level data from a large real‐world US‐based database, patients diagnosed with mccRCC, who received any PD‐1/L1‐based combination in first‐line (1L) setting, followed by second‐line (2L) therapy with either cabozantinib alone or in combination with PD‐1/L1 inhibitors were included. Patients given a cabozantinib‐containing regimen in 1L were excluded. The study end points were real‐world time to next therapy (rwTTNT) and real‐world overall survival (rwOS) by 2L.

Results

Of 12,285 patients with metastatic renal cell carcinoma in the data set, 348 patients met eligibility and were included in the analysis. After propensity score matching weighting, cabozantinib with PD‐1/L1 inhibitors versus cabozantinib (ref.) had similar rwTTNT and rwOS in the 2L setting. Hazard ratios and 95% confidence interval (CI) for rwTTNT and rwOS are 0.74 (95% CI, 0.49–1.12) and 1.15 (95% CI, 0.73–1.79), respectively.

Conclusion

In this study, the results align with the phase 3 CONTACT‐03 trial results, which showed no additional benefit of adding PD‐L1 inhibitor to cabozantinib compared to cabozantinib alone in 2L following PD‐1/L1–based therapies in 1L. These results from real‐world patients strengthen the evidence regarding the futility of rechallenge with PD‐1/L1 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellPyridinesAnilidesImmune Checkpoint InhibitorsKidney NeoplasmsHumansMaleFemaleMiddle AgedAgedAntineoplastic Combined Chemotherapy ProtocolsDisease ProgressionB7-H1 AntigenRetrospective Studies

Stichwörter der Autor:innen

immune checkpoint inhibitorsimmunotherapymetastasisrenal cell carcinomasurvival outcomestherapytyrosine kinase inhibitors

Substanzen

cabozantinibPyridinesAnilidesImmune Checkpoint InhibitorsB7-H1 Antigen

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, USA.
  • Division of Medical Oncology, University of Kansas Cancer Center, Kansas City, Kansas, USA.

ORCID-Profile: Georges Gebrael, Nishita Tripathi, Blake Nordblad, Gliceida Galarza Fortuna, Benjamin L Maughan

Zitieren

APA

Gebrael, G., Jo, Y., Mathew Thomas, V., Li, H., Sayegh, N., Tripathi, N., Srivastava, A., Nordblad, B., Dal, E., Narang, A., Brundage, J., Campbell, P., Galarza Fortuna, G., Hage Chehade, C., Maughan, B. L., Agarwal, N., & Swami, U. (2024). Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor. Cancer. https://doi.org/10.1002/cncr.35302

Vancouver

Gebrael G, Jo Y, Mathew Thomas V, Li H, Sayegh N, Tripathi N, et al. Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor. Cancer. 2024. doi:10.1002/cncr.35302

BibTeX
@article{Gebrael2024,
  author = {Gebrael, Georges and Jo, Yeonjung and Mathew Thomas, Vinay and Li, Haoran and Sayegh, Nicolas and Tripathi, Nishita and Srivastava, Ayana and Nordblad, Blake and Dal, Emre and Narang, Arshit and Brundage, James and Campbell, Patrick and Galarza Fortuna, Gliceida and Hage Chehade, Chadi and Maughan, Benjamin L and Agarwal, Neeraj and Swami, Umang},
  title = {Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35302}
}
Kostenlos starten →